Biocon
Biocon Limited, a leading biopharmaceutical company headquartered in Bengaluru, India, has established itself as a key player in the global biotechnology industry since its founding in 1978. With a strong focus on biopharmaceuticals, biosimilars, and novel biologics, Biocon operates across major regions including Asia, Europe, and North America. The company is renowned for its innovative products, particularly in the fields of diabetes, oncology, and autoimmune diseases. Biocon's commitment to affordability and accessibility sets it apart, making significant strides in providing high-quality healthcare solutions. Notable achievements include the launch of India's first biosimilar monoclonal antibody and recognition as a pioneer in the biosimilars market. With a robust pipeline and a reputation for excellence, Biocon continues to shape the future of biotechnology on a global scale.
DitchCarbon Score
How does Biocon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocon's score of 43 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biocon's reported carbon emissions
In 2024, Biocon Limited reported total carbon emissions of approximately 96,192,000 kg CO2e, with Scope 1 emissions at about 8,256,000 kg CO2e, Scope 2 emissions at approximately 87,936,000 kg CO2e, and Scope 3 emissions reaching about 156,387,000 kg CO2e. This represents a significant increase from 2023, when total emissions were approximately 131,095,000 kg CO2e, with Scope 1 at about 31,456,000 kg CO2e, Scope 2 at approximately 31,809,000 kg CO2e, and Scope 3 at about 67,830,000 kg CO2e. Biocon has set ambitious climate commitments, aiming for a 25% reduction in Scope 1 and Scope 2 emissions by the end of FY29, using FY20 as the baseline. This target reflects a proactive approach to mitigating their carbon footprint. Additionally, Syngene, a subsidiary, has committed to a 50% reduction in GHG emissions by FY33 for both Scope 1 and Scope 2 emissions. The company’s emissions data is not cascaded from any parent organization, indicating that these figures are independently reported. Biocon's ongoing efforts to address climate change demonstrate a commitment to sustainability and responsible environmental stewardship within the biopharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 55,997,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 127,530,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biocon is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
